Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Gamida Cell Ltd. (GMDA)

1.43   -0.12 (-7.74%) 12-05 16:00
Open: 1.53 Pre. Close: 1.55
High: 1.53 Low: 1.4
Volume: 504,024 Market Cap: 106(M)

Technical analysis

as of: 2022-12-06 8:18:27 AM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 2.17     One year: 2.56
Support: Support1: 1.32    Support2: 1.09
Resistance: Resistance1: 1.86    Resistance2: 2.2
Pivot: 1.66
Moving Average: MA(5): 1.52     MA(20): 1.7
MA(100): 2.06     MA(250): 2.51
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 22     %D(3): 25.5
RSI: RSI(14): 35.4
52-week: High: 4.71  Low: 1.32
Average Vol(K): 3-Month: 515 (K)  10-Days: 662 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GMDA ] has closed above bottom band by 14.4%. Bollinger Bands are 19.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.53 - 1.54 1.54 - 1.55
Low: 1.38 - 1.39 1.39 - 1.4
Close: 1.41 - 1.43 1.43 - 1.45

Company Description

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Headline News

Mon, 05 Dec 2022
GMDA Archives - develpment.analyticsinsight.net

Mon, 05 Dec 2022
De-siltation Scam Questions Proper Implementation Of Mission Flood Free In Guwahati - Guwahati Plus

Sun, 04 Dec 2022
Guwahati Metropolitan Development Authority (GMDA) sealed Illegally-built building - Sentinelassam - The Sentinel Assam

Sat, 03 Dec 2022
DRIIV & GMDA join hands to implement environmental sustainability initiatives - The Statesman

Tue, 29 Nov 2022
GMDA to renovate 2.2km long master sewer line along NH-8 - Hindustan Times

Mon, 28 Nov 2022
Should You Buy Gamida Cell Ltd (GMDA) Stock on Monday? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 76 (M)
Shares Float 50 (M)
% Held by Insiders 20.2 (%)
% Held by Institutions 33.2 (%)
Shares Short 3,410 (K)
Shares Short P.Month 2,300 (K)

Stock Financials

EPS -1.54
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.18
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -34.8
Return on Equity (ttm) -270.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.02
Qtrly Earnings Growth 0
Operating Cash Flow -75 (M)
Levered Free Cash Flow -50 (M)

Stock Valuations

PE Ratio -0.94
PEG Ratio 0
Price to Book value 7.94
Price to Sales 0
Price to Cash Flow -1.47

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.